Literature DB >> 27771887

Macrophage Migration Inhibitory Factor (MIF): Biological Activities and Relation with Cancer.

Camila Cristina Guimarães Nobre1, Josélio Maria Galvão de Araújo1, Thales Allyrio Araújo de Medeiros Fernandes2,3, Ricardo Ney Oliveira Cobucci1,4, Daniel Carlos Ferreira Lanza5, Vânia Sousa Andrade1, José Veríssimo Fernandes6.   

Abstract

Macrophage migration inhibitory factor (MIF) emerged in recent years as an important inflammation mediator, playing a prominent role in the pathogenesis of various types of malignant neoplasm. MIF is a glycoprotein that presents a wide spectrum of biological activities and exerts a complex interaction with various cellular signaling pathways, causing imbalance of homeostasis. Experimental and clinical studies show that high levels of MIF are found in almost all types of human cancers and are implicated in seemingly all stages of development of the tumors. The production of MIF is triggered through an autocrine signal emitted by tumor cells, and stimulates the production of cytokines, chemokines, and growth as well as angiogenic factors that lead to growth of the tumor, increasing its aggressiveness and metastatic potential. MIF is produced by virtually all types of human body cells, in response to stress caused by different factors, leading to pathological conditions such as chronic inflammation and immunomodulation with suppression of immune surveillance and of immune response against tumors, angiogenesis, and carcinogenesis. In this review, we present recent advances on the biological activity of MIF, the signaling pathways with which it is involved and their role in tumorigenesis.

Entities:  

Keywords:  Inflammation; Macrophage migration inhibitory factor; Neoplasms; Tumorigenesis

Mesh:

Substances:

Year:  2016        PMID: 27771887     DOI: 10.1007/s12253-016-0138-6

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  93 in total

Review 1.  Maintenance and differentiation of neural stem cells.

Authors:  Katlin B Massirer; Cassiano Carromeu; Karina Griesi-Oliveira; Alysson R Muotri
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2011 Jan-Feb

2.  Oxidoreductase Macrophage Migration Inhibitory Factor is simultaneously increased in leukocyte subsets of patients with severe sepsis.

Authors:  Lutz E Lehmann; Stefan U Weber; Dagmar Fuchs; Malte Book; Sven Klaschik; Jens-Christian Schewe; Andreas Hoeft; Frank Stüber
Journal:  Biofactors       Date:  2008       Impact factor: 6.113

3.  Macrophage migration inhibitory factor (MIF)--its role in catecholamine metabolism.

Authors:  J Matsunaga; D Sinha; F Solano; C Santis; G Wistow; V Hearing
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  1999-11       Impact factor: 1.770

4.  Macrophage migration inhibitory factor (MIF) enzymatic activity and lung cancer.

Authors:  Leona Mawhinney; Michelle E Armstrong; Ciaran O' Reilly; Richard Bucala; Lin Leng; Gunter Fingerle-Rowson; Darren Fayne; Michael P Keane; Aisling Tynan; Lewena Maher; Gordon Cooke; David Lloyd; Helen Conroy; Seamas C Donnelly
Journal:  Mol Med       Date:  2015-04-16       Impact factor: 6.354

5.  Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D.

Authors:  Mathias Krockenberger; Yvonne Dombrowski; Claudia Weidler; Monika Ossadnik; Arnd Hönig; Sebastian Häusler; Heike Voigt; Jürgen C Becker; Lin Leng; Alexander Steinle; Michael Weller; Richard Bucala; Johannes Dietl; Jörg Wischhusen
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

6.  Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer.

Authors:  Katherine L Meyer-Siegler; Kenneth A Iczkowski; Pedro L Vera
Journal:  BMC Cancer       Date:  2005-07-06       Impact factor: 4.430

7.  The role of tumor-associated macrophages in tumor vascularization.

Authors:  Chunqing Guo; Annicole Buranych; Devanand Sarkar; Paul B Fisher; Xiang-Yang Wang
Journal:  Vasc Cell       Date:  2013-12-06

Review 8.  Chronic inflammation and cytokines in the tumor microenvironment.

Authors:  Glauben Landskron; Marjorie De la Fuente; Peti Thuwajit; Chanitra Thuwajit; Marcela A Hermoso
Journal:  J Immunol Res       Date:  2014-05-13       Impact factor: 4.818

9.  Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis.

Authors:  Thorsten Hagemann; Stephen C Robinson; Richard G Thompson; Kellie Charles; Hagen Kulbe; Frances R Balkwill
Journal:  Mol Cancer Ther       Date:  2007-07       Impact factor: 6.261

10.  Involvement of macrophage migration inhibitory factor and its receptor (CD74) in human breast cancer.

Authors:  Vincent Richard; Nadège Kindt; Christine Decaestecker; Hans-Joachim Gabius; Guy Laurent; Jean-Christophe Noël; Sven Saussez
Journal:  Oncol Rep       Date:  2014-06-16       Impact factor: 3.906

View more
  37 in total

1.  PRMT6 Promotes Lung Tumor Progression via the Alternate Activation of Tumor-Associated Macrophages.

Authors:  Sreedevi Avasarala; Pei-Ying Wu; Samia Q Khan; Su Yanlin; Michelle Van Scoyk; Jianqiang Bao; Alessandra Di Lorenzo; Odile David; Mark T Bedford; Vineet Gupta; Robert A Winn; Rama Kamesh Bikkavilli
Journal:  Mol Cancer Res       Date:  2019-10-16       Impact factor: 5.852

2.  MIF/CD74 axis participates in inflammatory activation of Schwann cells following sciatic nerve injury.

Authors:  Honghua Song; Ziwen Zhu; Yue Zhou; Nan Du; Tiancheng Song; Hao Liang; Xiaojun Chen; Yingjie Wang; Yongjun Wang; Yuming Hu
Journal:  J Mol Histol       Date:  2019-06-13       Impact factor: 2.611

3.  Optimization of Pyrazoles as Phenol Surrogates to Yield Potent Inhibitors of Macrophage Migration Inhibitory Factor.

Authors:  Vinay Trivedi-Parmar; Michael J Robertson; José A Cisneros; Stefan G Krimmer; William L Jorgensen
Journal:  ChemMedChem       Date:  2018-04-23       Impact factor: 3.466

4.  Adding a Hydrogen Bond May Not Help: Naphthyridinone vs Quinoline Inhibitors of Macrophage Migration Inhibitory Factor.

Authors:  Thomas K Dawson; Pawel Dziedzic; Michael J Robertson; José A Cisneros; Stefan G Krimmer; Ana S Newton; Julian Tirado-Rives; William L Jorgensen
Journal:  ACS Med Chem Lett       Date:  2017-11-14       Impact factor: 4.345

Review 5.  Proteomic Research on the Antitumor Properties of Medicinal Mushrooms.

Authors:  Boris Jakopovic; Nada Oršolić; Ivan Jakopovich
Journal:  Molecules       Date:  2021-11-05       Impact factor: 4.411

6.  Investigation of the effects of downregulation of jumping translocation breakpoint (JTB) protein expression in MCF7 cells for potential use as a biomarker in breast cancer.

Authors:  Madhuri Jayathirtha; Anca-Narcisa Neagu; Danielle Whitham; Shelby Alwine; Costel C Darie
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

7.  MIF/SCL3A2 depletion inhibits the proliferation and metastasis of colorectal cancer cells via the AKT/GSK-3β pathway and cell iron death.

Authors:  Guan Huang; Lili Ma; Lan Shen; Yan Lei; Lili Guo; Yongjian Deng; Yanqing Ding
Journal:  J Cell Mol Med       Date:  2022-05-13       Impact factor: 5.295

8.  Synergistic Action of Diclofenac with Endotoxin-Mediated Inflammation Exacerbates Intestinal Injury in Vitro.

Authors:  Wen Li Kelly Chen; Emily Suter; Hikaru Miyazaki; Jason Velazquez; Douglas A Lauffenburger; Linda G Griffith; Rebecca L Carrier
Journal:  ACS Infect Dis       Date:  2021-03-21       Impact factor: 5.578

9.  Enhanced Mortality to Metastatic Bladder Cancer Cell Line MB49 in Vasoactive Intestinal Peptide Gene Knockout Mice.

Authors:  Niely Mirsaidi; Matthew P Burns; Steve A McClain; Edward Forsyth; Jonathan Li; Brittany Dukes; David Lin; Roxanna Nahvi; Jheison Giraldo; Megan Patton; Ping Wang; Ke Lin; Edmund Miller; Timothy Ratliff; Sayyed Hamidi; Scott Crist; Ken-Ichi Takemaru; Anthony Szema
Journal:  Front Endocrinol (Lausanne)       Date:  2017-08-07       Impact factor: 5.555

10.  MIF promoter polymorphism increases peripheral blood expression levels, contributing to increased susceptibility and poor prognosis in hepatocellular carcinoma.

Authors:  Lifeng Qin; Jinmei Qin; Xiaoping Lv; Caiqiao Yin; Qian'e Zhang; Jiqiao Zhang
Journal:  Oncol Lett       Date:  2021-05-24       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.